GCI Health

Wendy Lund

Report by Wendy Lund

Chief executive officer

GCI Health, WPP’s global specialty healthcare PR agency, drove continued momentum throughout 2013, establishing a larger geographic footprint, expanding key practice areas and growing our account base. A key focus was continued collaboration with WPP client teams to develop and execute integrated programming, with excellent results. We were also extremely honored this year to be named one of the Top Five Healthcare Agencies in the World by The Holmes Report . In 2014, our vision continues to concentrate on being the No.1 specialty healthcare PR agency.

A key focus was continued collaboration with WPP client teams to develop and execute integrated programming, with excellent results

To support the increasing demand for a global network, GCI Health opened its London office in 2013, bringing exceptional talent to our work outside the US. This expansion allows us to better serve our growing global and European client base and further build on our agency’s reputation for unsurpassed results, our emphasis on exemplary client service, unrivaled talent and forward-thinking capabilities.

As digital integration into traditional healthcare public relations becomes more essential, we broadened the strategic vision of GCI Health’s digital and social media offerings by enhancing our products and services and expanding our focus on social and mobile engagement. In adding a new digital lead, we are ensuring that our teams are able to be at the forefront of these dynamic digital elements of healthcare communications.

In 2014, GCI Health continues to focus on ‘putting patients first.’ With access to more information than ever before, patients are now more empowered. For some time, we have been shifting our traditional approaches of brand- or disease-state focus to one centered on patient engagement and activation, and we continually ask ourselves the important questions that will best ensure that we stay on a path with the patient at its core, while continuing to support critical scientific discoveries, commercially available treatments and providers and insurers.

Chapter 6 of 13

46%